MOSCOW, March 5. /TASS/. Mass inoculation with the EpiVacCorona vaccine developed by Russia’s State Research Center of Virology and Biotechnology Vector will begin in the second half of March, the center’s Director General Rinat Maksyutov told Vesti news show on Rossiya 1 Friday.

"Our fellow citizens will be able to get vaccinated [with EpiVacCorona] starting in the second half of March," he said.

In October 2020, EpiVacCorona became the second coronavirus vaccine registered in Russia. The vaccine consists of artificially synthesized short fragments of viral proteins - peptides - that make the immune system recognize and neutralize the virus.